Table 1 Baseline characteristics.
Variables | Conventional (n = 218) | Agg.minimization (n = 32) | Minimization (n = 161) | High exposure (n = 101) | P |
|---|---|---|---|---|---|
Age, year | 55.5 (51.0–61.0) | 57.5 (51.0–64.5) | 57.0 (53.0–63.0) | 53.0 (49.0–59.0) | < 0.001 |
Sex, female | 39 (17.9) | 9 (28.1) | 34 (21.1) | 14 (13.9) | 0.277 |
BMI, kg/m2 | 23.9 (22.3–25.8) | 23.7 (21.6–26.1) | 24.0 (22.1–26.5) | 24.2 (22.5–25.8) | 0.797 |
Underlying for HCC | 0.029 | ||||
Hepatitis B | 168 (77.1) | 22 (68.8) | 117 (72.7) | 91 (90.1) | |
Hepatitis C | 21 (9.6) | 3 (9.4) | 14 (8.7) | 4 (4.0) | |
Non-B, Non C | 29 (13.3) | 7 (21.9) | 30 (18.6) | 6 (5.9) | |
ABO incompatibility | 41 (18.8) | 5 (15.6) | 28 (17.4) | 6 (5.9) | 0.026 |
Hypertension | 58 (26.6) | 16 (50.0) | 56 (34.8) | 22 (21.8) | 0.004 |
Diabetes mellitus | 54 (24.8) | 9 (28.1) | 41 (25.5) | 21 (20.8) | 0.807 |
Pre-transplant MELD | 10 (8–14) | 11 (8–20) | 12 (8–16) | 9.0 (7–12) | 0.001 |
Donor type | 0.284 | ||||
Living | 170 (78.0) | 26 (81.2) | 135 (83.9) | 75 (74.3) | |
Deceased | 48 (22.0) | 6 (18.8) | 26 (16.1) | 26 (25.7) | |
Donor age, year | 32.0 (25.0–43.0) | 42.0 (30.5–50.5) | 34.0 (25.0–43.0) | 33.0 (25.0–43.0) | 0.107 |
Donor sex, female | 81 (37.2) | 14 (43.8) | 66 (41.0) | 30 (29.7) | 0.225 |
Graft steatosis > 10% | 5.0 (0.0–5.0) | 5.0 (0.0–5.0) | 5.0 (0.0–5.0) | 5.0 (0.0–5.0) | 0.689 |
AFP, ng/mL | 6.5 (3.5–21.8) | 8.0 (3.3–28.9) | 5.6 (2.9–18.7) | 11.0 (4.0–52.7) | 0.009 |
PIVKA II, mAU/mL | 31.5 (18.0–81.0) | 113.5 (34.0–320.0) | 38.0 (22.0–95.0) | 28.0 (17.0–65.0) | < 0.001 |
Salvage LT | 36 (16.5) | 2 (6.2) | 17 (10.6) | 19 (18.8) | 0.104 |
Bridging treatment | < 0.001 | ||||
None | 116 (53.2) | 12 (37.5) | 94 (58.4) | 73 (72.3) | |
Locoregional | 76 (34.9) | 8 (25.0) | 39 (24.2) | 22 (21.8) | |
Systemic or radiotherapy | 26 (11.9) | 12 (37.5) | 28 (17.4) | 6 (5.9) | |
Total necrosis | 37 (17.0) | 5 (15.6) | 33 (20.5) | 13 (12.9) | 0.454 |
Viable tumor number | 1.0 (1.0–3.0) | 1.0 (1.0–4.0) | 1.0 (1.0–3.0) | 2.0 (1.0–3.0) | 0.454 |
Maximum viable tumor size | 1.7 (1.0–2.5) | 1.8 (1.1–3.5) | 1.6 (0.9–2.6) | 1.9 (1.0–3.0) | 0.361 |
Sum of viable tumor size | 2.5 (1.0–4.5) | 2.2 (1.1–6.5) | 2.3 (0.9–5.1) | 3.0 (1.3–5.7) | 0.348 |
Microvascular invasion | 44 (20.2) | 8 (25.0) | 35 (21.7) | 27 (26.7) | 0.533 |
Poor differentiation | 53 (24.3) | 16 (50.0) | 58 (36.0) | 26 (25.7) | 0.003 |
Satellite nodule | 16 (7.3) | 3 (9.4) | 14 (8.7) | 18 (17.8) | 0.030 |
Above Milan criteria | 58 (26.6) | 11 (34.4) | 44 (27.3) | 29 (28.7) | 0.702 |
French risk score > 2 | 52 (23.9) | 12 (37.5) | 42 (26.1) | 33 (32.7) | 0.205 |
